Nasdaq

Applied Therapeutics to Present Full 12-Month INSPIRE Phase 3 Trial Results for Govorestat at PNS 2025 Annual Meeting

Applied Therapeutics will present new data from the INSPIRE trial for govorestat at the PNS Annual Meeting in May 2025. Applied Therapeutics, Inc. announced that it will present the full 12-month ...
Nasdaq

Applied Therapeutics Presents Positive 24-Month Data for Govorestat in CMT-SORD at PNS 2025 Annual Meeting

Applied Therapeutics, Inc. announced promising 18 and 24-month results from the INSPIRE Phase 2/3 trial of govorestat, a treatment for Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD).
Seeking Alpha

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at ...

Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb ...
WDTN

Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD ...

Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05) Sustained, statistically significant reduction in sorbitol in ...
FOX40 News

Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16 ...